Core Viewpoint - Merck announced the presentation of new clinical and real-world data supporting the long-term effectiveness of its 9-valent HPV vaccine, GARDASIL®9, and its 4-valent HPV vaccine, GARDASIL, against certain HPV-related cancers and diseases at the EUROGIN International conference [1]. Group 1 - The company is reaffirming the effectiveness of its HPV vaccines through new data [1]. - GARDASIL®9 is a 9-valent Human Papillomavirus vaccine, while GARDASIL is a 4-valent version [1]. - The presentation will take place at the EUROGIN International conference, highlighting the importance of the findings [1].